Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of BRAF mutations in Chinese patients with lung adenocarcinoma was approximately 1.5 %.
|
26202550 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Tumour-to-tumour metastasis from papillary thyroid carcinoma with BRAF mutation to lung adenocarcinoma with EGFR mutation: the utility of mutation-specific antibodies.
|
25556681 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Vemurafenib has shown significant activity in V600 mutant melanoma; however the role of this agent in Lung adenocarcinoma with an activating BRAF mutation is still evolving.
|
26045855 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The activating BRAF mutation p.V600E has been identified in many cancers, including colon and lung adenocarcinomas, papillary thyroid cancer, malignant melanoma, and hairy cell leukemia (HCL).
|
25583765 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations occurred in 2.2% of advanced-stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene.
|
25273224 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among the 204 lung ADCs tested, 11 cases (5.4%) carried HER2 exon 20 insertions and 4 cases (2.0%) had BRAF V600E mutation.
|
26102513 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combined genomic and proteomic analyses demonstrated infrequent alteration of validated lung cancer targets (including the absence of BRAF mutations in TTF1-negative LUAD), but identified novel potential targets for TTF1-negative LUAD, including KEAP1/Nrf2 and DNA repair pathways.
|
25878335 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma.
|
26200454 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
|
24888229 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Sixty-three patients were diagnosed with BRAF mutant lung adenocarcinomas between 2009 and 2013 (V600, 36; non-V600, 27).
|
25436800 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Gene alterations are significant in lung tumorigenesis, with certain genes (Kristen rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], and B-Raf proto-oncogene, serine/threonine kinase (BRAF)) possessing alterations important in the prognosis and treatment of lung adenocarcinoma.
|
25288236 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of this subset of NSCLC is similar to that of other genotype-defined subsets of lung adenocarcinoma (e.g. those with BRAF mutations, HER2 insertions, ROS1 rearrangements) and is a population of interest for trials of new targeted therapies.
|
23328547 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IHC using the VE1 clone and FLEX linker is a specific method for the detection BRAF V600E and may be an alternative to molecular biology for the detection of mutations in lung adenocarcinomas.
|
23927882 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this series, 230 resected lung adenocarcinomas from smoker (>100 cigarettes in lifetime) at single center (Shanghai Cancer Center, Shanghai, China) were tested for mutation in EGFR, KRAS, BRAF, HER2, EML4-ALK and PIK3CA.
|
23098378 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
|
24035431 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study compared the specificity and sensitivity of IHC with other methods for the detection of BRAF(V600E) in primary lung adenocarcinoma.
|
23131393 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
104 consecutively resected lung adenocarcinomas from 396 non-smoker females (less than 100 cigarettes in a lifetime) at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, EML4-ALK, KRAS, HER2, BRAF, and PIK3CA.
|
22707299 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.
|
22135231 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
CTD_human |
We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.
|
22135231 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
|
22773810 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We undertook this study to determine the clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
|
21483012 |
2011 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to prospectively characterize the incidence of KRAS and BRAF mutations in EGFR FISH-positive surgically treated lung adenocarcinomas.
|
20381121 |
2010 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this surgical series, 52 resected lung adenocarcinomas from never-smokers (< 100 cigarettes in a lifetime) at a single institution (Fudan University, Shanghai, China) were analyzed concurrently for mutations in EGFR, KRAS, NRAS, HRAS, HER2, BRAF, ALK, PIK3CA, TP53 and LKB1.
|
20855837 |
2010 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
|
18636014 |
2008 |